ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options

EML4-ALK Fusion Lung Cancer: A Rare Acquired Event

(2015) Sven Perner et al.   NEOPLASIA

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

(2013) Andrew J. Weickhardt et al.   CANCER

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

(2013) Eamon M. Berge et al.   Clinical Lung Cancer

LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor

(2013) Jianyong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

(2013) Soyeon Kim et al.   Journal of Thoracic Oncology

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK

(2012) Hui-Yong Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

(2012) Chris M.J. Conklin et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

(2011) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors

(2011) Youngil Koh et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

(2011) D. Ross Camidge et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer

(2011) Jeong-Ok Lee et al.   Journal of Thoracic Oncology

ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity

(2011) Hideki Kimura et al.   LUNG CANCER

Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

(2010) Z. Chen et al.   CANCER RESEARCH

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

(2010) Kenichi Suda et al.   Journal of Thoracic Oncology

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

(2010) Xuchao Zhang et al.   Molecular Cancer

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

(2009) Maria Paola Martelli et al.   AMERICAN JOURNAL OF PATHOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas

(2009) Jennifer M. Boland et al.   HUMAN PATHOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

(2009) D. Bixby et al.   Hematology-American Society of Hematology Education Program

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

(2008) Kazuya Shinmura et al.   LUNG CANCER